Budesonide granules 9 mg
Drugper day
NCT Number: NCT02142634
The purpose of this study is to demonstrate the efficacy of budesonide for the treatment of active incomplete microscopic colitis.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 3
Centre for Digestive Diseases, Hamburg, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
per day
per day
Time frame: 8 weeks
Time frame: 2 weeks
Time frame: 6 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Dr. Falk Pharma GmbH
Industry
Randomised, Double-blind, Placebo-controlled, Multi-centre Trial on the Efficacy and Safety of Budesonide for Induction of Remission in Incomplete Microscopic Colitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.